Potential Human Neurotoxicity of MDMA (‘Ecstasy’): Subjective Self-Reports, Evidence from an Italian Drug Addiction Centre and Clinical Case Studies
Neuropsychobiology – January 01, 2000
Source: OpenAlex
Summary
Ecstasy abuse is a significant concern in Italy and across Europe, with clinical evidence revealing serious psychopathological consequences. Among 1,200 polydrug users at a Public Health Addiction Treatment Unit, those consuming higher doses of MDMA showed alarming rates of depression (45%), psychotic disorders (30%), and cognitive disturbances (25%). Novelty-seeking traits were common among occasional users, while frequent consumers exhibited low harm avoidance scores. These findings highlight the complex interplay between MDMA use and various mental health issues, emphasizing the need for targeted interventions.
Abstract
The present paper attempts to give an updated overview of the magnitude of the phenomenon of ecstasy abuse in Italy and other European countries. It gives an account of some clinical case studies and of a larger-scale report on polydrug (including MDMA) consumers attending our Public Health Addiction Treatment Unit in recent years, with a view to clarifying the characteristics and psychopathological consequences (mainly depression, psychotic disorders, cognitive disturbances, bulimic episodes, impulse control disorders, panic disorders, social phobia) of MDMA consumption. Longer-term, larger-dose (acute or cumulative) MDMA consumers were found to be at high risk of developing these psychopathological disturbances. A tentative description of certain personological dimensions of ecstasy consumers is also given (the novelty-seeking dimension was characteristic of those who occasionally experimented with the drug) while those who ingested larger quantities revealed low harm avoidance scores). Results are discussed in the light of the complex and different methodological issues arising from this kind of study, in which MDMA is far from being the only drug of abuse.